8-K
filed June 1, 2026, 7:00 AM ET
ticker ELOX
CIK 0001035354
other material
confidence high
sentiment negative
materiality 0.75
Eloxx Pharma: 1-for-11 reverse stock split effective May 29; appoints two independent directors
Eloxx Pharmaceuticals, Inc.
- Board approved 1-for-11 reverse stock split effective May 29, 2026; authorized shares reduced from 500M to 100M.
- Stockholders holding 57.1% of shares approved via written consent on April 28, 2026.
- Appointed Stephen W. Webster (former CFO of Spark Therapeutics) and Nina Kjellson (Canaan Partners GP) to Board.
- Board reduced from six to five directors; each new director received an option to purchase 13,587 shares.
- Common stock trading on OTC Pink under symbol ELOX will begin split-adjusted on June 1, 2026.
Key facts
Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Eloxx Pharmaceuticals, Inc. issued 2,500,000 shares of warrant to such investors.
- Security
- warrant
- Shares
- 2,500,000 shares
- Purchaser
- such investors
Exact text from the filing
On May 27, 2026, such investors exchanged 2,500,000 shares of Common Stock issued in the Prefunded Warrant Exercise for prefunded warrants to purchase an equal number of shares of Common Stock
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Eloxx Pharmaceuticals, Inc. issued 2,500,000 shares of common stock to certain of the investors.
- Security
- common stock
- Shares
- 2,500,000 shares
- Purchaser
- certain of the investors
Exact text from the filing
On April 27, 2026, certain of the investors exercised pre-funded warrants to purchase an aggregate of 2,500,000 shares of Common Stock
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Eloxx Pharmaceuticals, Inc. issued 54,076,677 shares of warrant to the investors party thereto.
- Security
- warrant
- Shares
- 54,076,677 shares
- Purchaser
- the investors party thereto
Exact text from the filing
the Company issued and sold prefunded warrants to purchase an aggregate of 54,076,677 shares of common stock
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Stephen W. Webster was appointed as Director at Eloxx Pharmaceuticals, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) appointed Stephen W. Webster and Nina Kjellson to fill vacancies on the Board
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Nina Kjellson was appointed as Director at Eloxx Pharmaceuticals, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) appointed Stephen W. Webster and Nina Kjellson to fill vacancies on the Board
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Eloxx Pharmaceuticals, Inc.: Approved reverse stock split at a ratio between 1-for-2 and 1-for-20, with exact ratio determined by the Board; Board later approved a 1-for-11 reverse stock split and a reduction of authorized shares from 500,000,000 to 100,000,000 effective 5:00 p.m. ET on May 29, 2026 (effective 2026-05-29).
- Change
- charter amendment
- Effective
- 2026-05-29
Exact text from the filing
On May 29, 2026, the Company filed with the Secretary of State of the State of Delaware (the "Delaware Secretary of State") a Certificate of Amendment to its Certificate of Incorporation (the "Certificate of Amendment") to effect the Reverse Stock Split and Authorized Share Reduction.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.